2022 ACR/EULAR Classification Criteria for GCA Dr. Michael Putman discusses interesting take-home messages from the Vasculitis Investigators Meeting at ACR22 Convergence regarding the 2022 ACR/EULAR Classification Criteria for GCA. https://t.co/FL9FGhWcxB https://t.co/JKi7Nn4O2O

• https://bit.ly/3ElZJRl

Avoid Abatacept in RA patients with a history of cancer? Dr. Richard Conway ( @RichardPAConway ) discusses abstracts #0267 and #0255 presented at #ACR22. https://t.co/1lC33XlBt7 https://t.co/ttUQaTVF43

• https://bit.ly/3ggXPcy

Anifrolumab shows long-term promise in patients with lupus Researchers report positive results from the first placebo-controlled long-term trial of anifrolumab—a human monoclonal antibody that targets the type I IFN receptor—in patients with lupus. https://t.co/IlgEUKkMOv https://t.co/kpSt61d5Qx

• https://bit.ly/3EoB6Dx

Effect of voclosporin in class V lupus nephritis Dr. Yusof ( @Yuz6Yusof) discusses abstract 0355 presented at #ACR22. Abstract 0355: Long-term Use of Voclosporin in Patients with Class V Lupus Nephritis: Results from the AURORA 2 Continuation Study https://t.co/sH04dhBskS https://t.co/mUOrJKdYBF

• https://bit.ly/3GqHf4I

#ACR22 - Day 1 https://t.co/GlEhTnKXm7 https://t.co/JFyMSpjFq3

• https://bit.ly/3gnq35l

JAK vs TNF inhibitor Infections in RA Dr. David Liew ( @drdavidliew) discusses abstract 0302 at #ACR22 Convergence. Abstract 0302: Risk of Infections Between JAK Inhibitors and TNF Inhibitors Among Patients with Rheumatoid Arthritis https://t.co/ipD5ON7BJ7 https://t.co/rRD5wqHhFk

• https://bit.ly/3XsRCLB

#ACR22 Appraisal, Praise & Critique Dr. Cush talks ACR22, the highs and the lows. https://t.co/1SVr2LLOcG https://t.co/PqcMix7O1f

• https://bit.ly/3V5VtMs

Retrospective review of 265 ILD pts - 9.8% were ANCA positive (PR3, MPO). ANCA- oft called IPF. ANCA+ CTD-ILD and 65% evolved into AAV (29% AAV follwed ILD Dx). No lung diff betw Pos v Neg pts, but ANCA+ had more drugs, hosp. #ACR22 https://t.co/X6UfiawfmW https://t.co/BZpTsjYAFW

• https://bit.ly/3EMc8zu

Breakthrough COVID infection in SLE during Omicron era Dr. Yusof ( @Yuz6Yusof) talks with Dr. Amit Saxena about abstract #2081 at #ACR22 Abstract 2081: COVID-19 Infections, Morbidity, and Seroreactivity in SLE Patients.... https://t.co/0OFcHK2PLj https://t.co/2ULOfSZUqU

• https://bit.ly/3Goj6M9

Opioids and Health Care Utilization in PsA and AS Dr Aurelie Najm ( @AurelieRheumo) discusses Abstract 0402 presented at #ACR22. Abstract 0402: Opioid Use and Healthcare Utilization in Adults with PsA and AS https://t.co/trruZGyIVf https://t.co/8kj9vpKPlD

• https://bit.ly/3TMFeTp

Dr. Ted Mikuls has authored a Clinical practive review of Gout in this weeks New England Journal of Medicine - Congrats Ted! https://t.co/8MuC6upkOT https://t.co/zO4nZbWQ5A

• https://bit.ly/3V4BI7U

Retrospective review of 185 hospitalized AOSD pts (incidence 0.16 - 0.21/100K); Mean age 47 (70% female), mean ESR 55, CRP 12.26, ferritin 7141 WBC 12.15, anemia 23%. 24% ICU care & overall mortality was 3.2%. Ab#0829 #ACR22 https://t.co/eDRY4b3GAg https://t.co/3pt0ZH5QQH

• https://bit.ly/3tKKxIC

Best of PsA on Day 1 Dr. Rachel Tate ( @uptoTate) discusses the best PSA data presented 11/12 at #ACR22 https://t.co/i93CX7wic3 https://t.co/dQDOcIsu1P

• https://bit.ly/3TIoZXu

#ACR22 - Day 2 Part III RheumNow and its reporters review abstracts presented on Day 2 of #ACR22. https://t.co/uUiX7s5Ajf https://t.co/0E5KSpOyyL

• https://bit.ly/3EKEMAE